{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65337aeb32aab9001268a81f/68b8c0faac09b9f650cc310d?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"API-CAT: Author interview with Prof. Isabelle Mahé","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/65337aeb32aab9001268a81f/1757965796852-9119d867-4a50-4a44-b1ee-0fc624de2372.jpeg?height=200","description":"<p>Prof. Isabelle Mahé is a cardiologist, triallist, and Professor of Internal Medicine Paris Cité University, France. She recently led the API-CAT study, a randomised controlled trial of apixaban 2.5 mg BD vs 5 mg BD for treatment of patients with cancer associated venous thromboembolism after 6 months of therapy. Pip and Rich discussed API-CAT in detail in episode 20 and now seize the opportunity to speak to an international expert and leader in the field about the art of the trial. </p><p><br></p><p><a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2416112\" rel=\"noopener noreferrer\" target=\"_blank\">API-CAT was published in the New England Journal of Medicine in 2025</a>,</p>","author_name":"Richard Buka"}